← Back to headlines
Novocure Raises 2026 Revenue Forecast on Strong Q1 and Optune Pax Launch
Novocure has raised its revenue guidance for 2026 to $690M-$710M, following a strong Q1 performance that beat expectations. The company's Optune Pax launch has seen 169 prescriptions in its first seven weeks, contributing to the positive outlook.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
